CNBC correspondent Dan Dorfman has speculated that Warner-Lambert and Schering-Plough will combine, but both companies have declined to comment on what they termed just a rumor.
While analysts agree that the talk was nothing more than a rumor, they still feel that such a move would make sense. James Keeney of Rodman & Renshaw said combining the two would be an analyst's dream. Both companies have pharmaceutical and over-the-counter divisions, with S-P stronger in the former and W-L in the latter.
"I really don't have any idea if it's going to happen," said Mr Keeney, "but just looking at the trends in the industry, I would say they would be a candidate." As has happened in many industries, he added, the mid-tiered companies are being bought up. Few in that range are left now, aside from these two companies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze